BioWorld

Jan. 16, 2008

View Archived Issues

XenoPort's RLS Drug Reduces Relapse Rate In Phase III Trial

Read More

Genentech Earnings Just OK, 'Flattish' 2008 Ahead: Analyst

Read More

Pervasis Gets $9.75M to Boost Blood Vessel Repair Candidate

Read More

Alfacell Deals U.S. Rights for Onconase to Strativa

Alfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million. (BioWorld Today) Read More

Novo Nordisk Halts Development of its Inhaled Insulin Program

Read More

Clinic Roundup

Read More

Other News To Note

Read More